Skip to main content

Evans John M.'s Form 4 filing

Beam Therapeutics Inc. (BEAM) · filed Jul 29, 2022

Accession no.
0000899243-22-027077
Filed
Jul 29, 2022
Trade date
Jul 28, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions. Open-market sales total $3.29M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Evans John M.CIK 0001786304Director, Officer (CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 28, 2022Common StockSSaleDisposed−10,181$64.87F2−$660,441.471,108,339Direct
Jul 28, 2022Common StockSSaleDisposed−15,236$65.82F3−$1,002,833.521,093,103Direct
Jul 28, 2022Common StockSSaleDisposed−1,562$66.74F4−$104,247.881,091,541Direct
Jul 28, 2022Common StockSSaleDisposed−2,848$67.80F5−$193,094.41,088,693Direct
Jul 28, 2022Common StockSSaleDisposed−173$68.49−$11,848.771,088,520Direct
Jul 28, 2022Common StockSSaleDisposed−6,953$64.88F6−$451,110.64136,047Indirect
Jul 28, 2022Common StockSSaleDisposed−10,599$65.92F7−$698,686.08125,448Indirect
Jul 28, 2022Common StockSSaleDisposed−201$66.61F8−$13,388.61125,247Indirect
Jul 28, 2022Common StockSSaleDisposed−2,247$67.82F9−$152,391.54123,000Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.42, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.43 to $66.34, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.44 to $67.37, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.45 to $67.87, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.38, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.46 to $66.45, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.50 to $66.61, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.72 to $68.49, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)